GALAPAGOS NV NPV ISIN BE0003818359 SEDOL B07Q2V5 GLPGF
COMMONSTOCK · Common Stock · CUSIP B44170106
Belgian pharmaceutical company
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 64.7m as of 2019-12-31, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $209.35.
Insider purchases and sales in Q4 2019
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q4 2019.
Holders, Q4 2019
| Manager | Shares | Change |
|---|---|---|
| GILDER GAGNON HOWE & CO LLC 1.46% of their portfolio | 673.5k $141.0m | — |